Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Campath-1H Consolidation After FMC Induction in T-CLL and T-PLL
NCT00278213Phase 2Completed
- Sponsor
- German CLL Study Group
- Start
- Sep 2002
- Primary completion
- Feb 2007
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and T-cell prolymphocytic leukemia (T-PLL), sponsored by German CLL Study Group. Primary endpoints: Severe adverse events and life-threatening infections and Remission rate. Started Sep 2002; status: completed.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)T-cell prolymphocytic leukemia (T-PLL)
Beyond the preview
Go deeper on NCT00278213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00278213.